Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 8Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Neoplasm Metastasis 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Cancers 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms × satraplatin × Clear all
NCT01259479 2018-07-05

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
9 enrolled
CNS

Brain Neoplasms, Neoplasms

NCT00313456 2012-05-10

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Agennix

Phase 1 Terminated
25 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Agennix

Phase 1 Terminated
28 enrolled
Tumor-Agnostic

Neoplasms

NCT00329329 2012-03-23

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Agennix

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡